# EXCLAIM (NCT02716116)

> A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: mobocertinib
- Indication: EGFR exon 20 insertion-positive non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02716116
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Takeda
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: TAK-788
- Enrollment: 324
- Primary outcome: Part 1, Dose Escalation Component: Recommended Phase 2 Dose (RP2D) of Orally Administered TAK-788
- Primary outcome: Part 2, Expansion Cohorts 1, 2, 4, 5 and 7: Confirmed Objective Response Rate (ORR) Assessed by the Investigator
- Primary outcome: Part 2, Expansion Cohort 3: Intracranial ORR (iORR) Assessed by Independent Review Committee (IRC)
- Primary outcome: Part 2, Expansion Cohort 6: Confirmed ORR Assessed by IRC
- Primary outcome: Part 3, Extension Cohort: Confirmed ORR Assessed by IRC

## Some of the questions raised in the 29 most recent indexed sources

_Automated from the 29 newest of 33 indexed sources (Apr 2019 – Jul 2025). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- How mobocertinib in this study compares with amivantamab in CHRYSALIS when no head-to-head data exist
- Which response figure applies when pooled cohorts and independent versus investigator review give different numbers
- Whether response in this study differs by exon 20 insertion variant

## Indexed commentary on EXCLAIM so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 26 posts on X
- 4 podcast episodes
- 3 YouTube videos

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=exclaim-nct02716116

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02716116", "email": "<work email>"}; the inbox owner confirms by the emailed link.
